ArticleJournal of thoracic disease2025
Diagnostic performance of metagenomics sequencing for pulmonary fungal infections: a clinical evaluation using the Nanopore platform.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The future of fungal diagnostics: What's next in laboratory testing for invasive fungal infection?Medical mycology · 2026Review
- Current status and prospects of nanopore sequencing technology in the detection of pathogenic microorganisms.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary fungal infections are becoming increasingly prevalent, particularly among immunocompromised patients. Traditional culture-based and serological diagnostic methods exhibit low sensitivity and prolonged turnaround times (TATs), highlighting the need for more efficient diagnostic approaches. This study aims to evaluate the diagnostic performance of metagenomic third-generation sequencing (mTGS) using the Oxford Nanopore platform (Oxford Nanopore Technologies) for the detection of fungal pathogens in lower respiratory tract infections, and to compare its effectiveness with conventional diagnostic methods. Methods: This study evaluated the clinical utility of mTGS with the Nanopore platform for diagnosing lower respiratory tract fungal infections (LRTFIs). Between January and August 2022, bronchoalveolar lavage fluid (BALF) samples were collected from 253 patients with suspected fungal infections across four medical centers in Hangzhou, China. Fungal detection was performed through both mTGS and conventional culture, and diagnostic performance was assessed via bioinformatics analysis and clinical adjudication. Results: Fungal infections were detected in 65 samples (29.3%), with 11 fungal species identified by mTGS, including Conclusions: mTGS on the nanopore platform offers a rapid, sensitive, and comprehensive approach for diagnosing LRTFIs, particularly in immunocompromised patients. It serves as a valuable complementary tool for detecting mixed infections or culture-negative pneumonia. However, careful interpretation is needed regarding the clinical relevance of colonizing fungi such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.